HKSTP Announces Comprehensive Upgrades of Incu-Bio Programme 

(Hong Kong, 9 October 2025) – Hong Kong Science and Technology Parks Corporation (HKSTP) today celebrated a new milestone with the official launch of its upgraded life and health tech focused Incubation Programme (Incu-Bio).  The enhanced Incu-Bio programme offers Asia’s most unique comprehensive support package, specially designed to help life and health tech and deep tech startups overcome R&D bottlenecks, accelerate commercialisation, and access global markets.

Forward-looking Strategy: Collaborative Ecosystem Drives Co-creation

As Asia’s most unique and end-to-end journey partner incubation programme for life and health tech, Incu-Bio focuses on tangible business outcomes through its four core FUEL pillars - Follow (continuous guidance), Upskill (capability building), Expose (market exposure), and Link (resource connection). The programme provides end-to-end support from laboratory research to regulatory activities, supported by a network of over 300 expert mentors across startup ecosystem, accelerating the entire process from concept to development, trials, fundraising, and commercialisation.  

HKSTP has also established co-incubation partnerships with global pharmaceutical and life and health tech leaders including Amgen, Boehringer Ingelheim Venture Fund (BIVF), Merck, Roche, Shanghai Pharmaceuticals (SPH).  These collaborations bring cutting-edge global technologies and resources to Hong Kong while driving commercial cooperation and joint innovation outcomes.  

Comprehensive Funding to World-Class Facilities Creates Global Life and Health Tech Hub

Hong Kong stands as the world’s second-largest biotech fundraising hub.  Over the past two years, life and health tech park companies accounted for approximately 33% of all our assisted fundraising activities within Science Park, demonstrating the life and health tech ecosystem’s robust potential. HKSTP offers a range of diverse programmes including Ideation, Incubation, Co-Acceleration, Clinical Translational Catalyst, and MedTech Co-Creation. These offer participating startups up to HK$ 39.7 million total funding support, to help the companies capture investment opportunities and accelerate business development.  

As Hong Kong’s largest innovation and technology ecosystem, HKSTP provides leading shared facilities. The Park also recently added over 25,000 sq.ft. of Biosafety Level 2 (BSL-2) laboratories and 30,000 square feet of office space, supporting nearly 100 startups across surgical robotics, gene therapy, and AI medical imaging.

Mr. Derek Chim, Head of Startup Ecosystem and Development of HKSTP, stated: “Hong Kong is entering a golden era of life & health technology innovation. Leveraging our city’s unique advantages of world-class research talent and vibrant capital market, together with our international business environment and close ties to the Greater Bay Area, HKSTP continuous to optimise Incu-Bio to build a seamless 'bench to bedside' industry chain. This enables startups to accelerate R&D and expand globally, further strengthening Hong Kong’s position as Asia’s leading life and health innovation hub.”

Success Stories: Demonstrate Hong Kong’s Innovation Strength

Incu-Bio has been launched for more than 15 years, and it has nurtured over 100 life and health tech companies, with translational innovations as follow:

• World's first robot-assisted en-bloc resection of bladder tumours - Agilis Robotics developed a fully flexible endoscopic surgical robot designed to streamline and simplify minimally invasive surgery in the gastrointestinal tract and urinary tract. The robotic system was used to perform the world's first robot-assisted en-bloc resection of bladder tumours in a local clinical trial. The company has raised US$ 17 million to date, setting the highest investment record in Incu-Bio’s history.
  
  
• AI drug discovery solution – AILSI leverages proprietary AI models and human multi-omics scientific data to discover novel disease targets and craft exceptionally innovative molecules, reducing drug development timelines.
  
  
• Gene therapy for genetic disorders and cancers - DanausGT is a gene editing company and has developed a unique complete gene replacement technology platform capable of curing diseases at the genetic level, including genetic disorders and cancers, now in pre-clinical trial stage.
  
  
• AI-powered real-time endoscopic imaging systems – Developed by Endovision, this system assists doctors in performing examinations more precisely. The solution has obtained EU regulatory certification (EU-MDR), significantly improving accuracy by standardised endoscopic examination.
  
  
• AI + XR visual-spatial guidance for surgeries – Syngular combines artificial intelligence (AI), extended reality (XR), and advanced game development technologies to quickly convert medical images such as CT and MRI scans into high-quality 3D holographic models. Doctors put on XR glasses during surgery and the holographic models are accurately "overlaid" on the patient's body. This mixed reality visual effect helps doctors determine the surgical site, reduce surgical time and surgical risks.